Business

Dr. Reddy’s Laboratories has acquired tobramycin inhalation solution from Teva Pharmaceutical Industries as part of the divestiture required by the US Federal Trade Commission (FTC) before Teva could acquire Allergan's generics business. Teva received FDA approval for itstobramycin inhalation solution in October 2013. As part of the same process, Allergan has … [Read more...] about Dr. Reddy’s, Impax acquire inhalation products as part of the Teva/Allergan divestiture

Adamis Pharmaceuticals says that it has received additional US and European patents for the Taper dry powder inhaler, which the company acquired from 3M Drug Delivery Systems in 2013. In January 2015, Adamis announced that it had received US and Japanese patents for the Taper DPI. The company says that it had received a notice of allowance from the USPTO for … [Read more...] about Adamis gets additional patents for Taper DPI

Altimmune has announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract worth up to $120.2 million over five years for clinical development of NasoShield intranasal anthrax vaccine. An initial amount of $14.3 million will fund a Phase 1 trial of NasoShield, with an additional $105.9 million available for … [Read more...] about Altimmune gets up to $120.2 million for development of NasoShield anthrax vaccine

US-based Cannabis Science has announced that it "will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers." According to the company, the product would be available "in states where marijuana is legal on a national basis." The announcement does not specify when or how such a release would occur but it asserts that over … [Read more...] about Cannabis Science says it will “release” a CBD/THC product for asthma and COPD patients in US

Vectura has filed a patent infringement suit against GlaxoSmithKline after GSK said that it would not exercise its option for additional patent licenses for various Ellipta DPI products under a 2010 agreement. Many of the patents covered in the agreement expire in 2016. Vectura says that GSK is infringing on US Patent No. 8,303,991, titled "Method of making … [Read more...] about Vectura sues GSK for patent infringement related to Ellipta licensing agreement

Advanced Inhalation Therapies (AIT), which is developing inhaled nitric oxide therapies for cystic fibrosis and other indications, has filed a request to withdraw its registration statement for an initial public offering. The company announced its initial filing for the IPO in August 2015, saying that it planned to raise up to $36 million to support Phase 2 … [Read more...] about Advanced Inhalation Therapies files to withdraw IPO

Smartinhaler maker Adherium has announced an upcoming $8 million AUD ($6 million USD) share placement to Fidelity International, increasing Fidelity's holdings in the company to 10%. The shares will be issued on July 26, 2016. According to Adherium, the purpose of the placement was to raise funds for working capital. Adherium CEO Garth Sutherland commented, … [Read more...] about Fidelity increases its holding in Adherium to 10%

Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential value of $3 million, supports development of the company's aerosolized KL4 surfactant as a treatment for radiation-induced lung … [Read more...] about Windtree Therapeutics gets $1 million for aerosolized KL4 surfactant development

Therapix Biosciences has entered into an agreement with the Hebrew University's technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university's Institute of Drug Research, the company said. The news comes one week after the company, which is developing cannabinoids … [Read more...] about Therapix Biosciences licenses intranasal cannabinoid formulation from Hebrew University